Trials / Withdrawn
WithdrawnNCT04268966
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
An Open-Label, Multicenter Study of the Safety and Tolerability of Brincidofovir (CMX001) for Post-Exposure Prophylaxis of Ebola Virus Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.
Detailed description
The primary objective of this study is to evaluate the safety and tolerability of BCV when administered for post-exposure prophylaxis of EVD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brincidofovir |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-11-01
- Completion
- 2015-12-01
- First posted
- 2020-02-13
- Last updated
- 2020-02-26
Source: ClinicalTrials.gov record NCT04268966. Inclusion in this directory is not an endorsement.